3B.1 Overview and rationale for the cost-minimisation approach
Page last updated: September 2016
Information Requests
- Summarise the key components and assumptions of the approach (Subsection 3B.1.1)
3B.1.1 Summary table of cost-minimisation approach
Complete Table 3B.1.1 to summarise the key assumptions and components of the cost-minimisation approach.
|
Component |
Claim or assumption |
|---|---|
|
Therapeutic claim: effectiveness |
Based on evidence presented in Section 2, effectiveness is assumed to be [noninferior/superior] |
|
Therapeutic claim: safety |
Based on evidence presented in Section 2, safety is assumed to be [noninferior/superior] |
|
Evidence base |
[direct randomised trials/indirect comparison of randomised trials] |
|
Equi-effective doses |
Proposed medicine [describe dose/day/course] and comparator [describe dose/day/course] |
|
Direct medicine costs |
[lower/equivalent/higher]; [cost of proposed medicine] vs [cost of comparator] (costs are per patient per course for an acute or self-limited therapy, or per patient per year for a chronic or continuing therapy) |
|
Other costs or cost offsets |
[Yes/No] [if yes; brief description – eg adverse effect–related costs, monitoring costs, administration costs] |